Table 3 Potential target agents identified based on protein-protein interaction networks of deregulated genes in infantile hemangioma
From: Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma
Gene symbol | Gene name | Selected target agent | Clinical relevance |
|---|---|---|---|
EDNRA | endothelin receptor type A | Zibotentan, Atrasentan | Colorectal [62], prostate [63] and renal cell [64] carcinomas |
IGF1R | insulin-like growth factor 1 receptor | Linsitinib, Ganitumab, Figitumumab, Dalotuzumab, Cixutumumab, Robatumumab | Adrenocortical [65], ovarian [66], non-small cell lung [67], colorectal [68, 69] carcinomas and soft tissue sarcoma [70] |
PDGFC | platelet derived growth factor C | Sunitinib | |
PDGFRA | platelet-derived growth factor receptor, alpha polypeptide | Motesanib, Ramucirumab, Midostaurin, Amuvatinib, Nintedanib, Pazopanib, Tandutinib, Crenolanib, Nilotinib, Masitinib, Sorafenib, Sunitinib, Regorafenib, Dovitinib, Telatinib, Vatalanib, Axitinib, Lenvatinib, Imatinib | Colorectal [73, 74], hepatocellular [75–78], kidney [79], non-small [80] and small cell lung [81], pancreatic [82–84], colon [85], gastrointestinal [86], renal cell [71, 87], breast [72, 88], melanoma [89], thyroid [90] carcinomas and soft tissue sarcoma [91] |
VEGFA | vascular endothelial growth factor A | Ziv-aflibercept, Bevacizumab, Sorafenib tosylate, Lenalidomide, Thalidomide, Aflibercept | Colorectal [92, 93] ovarian [94], non-small cell lung [95], hepatocellular [96] carcinomas and multiple myeloma [97] |